A novel mutation in early-onset sarcoidosis/Blau syndrome: an association with *Propionibacterium acnes*

Fumiko Okazaki¹, Hiroyuki Wakiguchi¹, Yuno Korenaga¹, Tamaki Nakamura¹, Hiroki Yasudo¹, Shohei Uchi², Ryoji Yanai², Nobuyuki Asano¹, Yoshinobu Hoshii³, Tsuyoshi Tanabe⁵, Kazushi Izawa⁶, Yoshitaka Honda⁶, Ryuta Nishikomori⁶, Keisuke Uchida⁶, Yoshinobu Eishi⁹, Shouichi Ohga⁹ and Shunji Hasegawa¹

Abstract

**Background:** Early-onset sarcoidosis (EOS) and Blau syndrome (BS) are systemic inflammatory granulomatous diseases without visible pulmonary involvement, and are distinguishable from their sporadic and familial forms. The diseases are characterized by a triad of skin rashes, symmetrical polyarthritis, and recurrent uveitis. The most common morbidity is ocular involvement, which is usually refractory to conventional treatment. A gain-of-function mutation in the nucleotide-binding oligomerization domain-containing protein 2 (NOD2) gene has been demonstrated in this disease; however, little is known about the relationship between the activation of NOD2 and the pathophysiology of EOS/BS. Here we describe EOS/BS with a novel mutation in the NOD2 gene, as well as detection of *Propionibacterium acnes* (*P. acnes*) in the granulomatous inflammation.

**Case presentation:** An 8-year-old Japanese girl presented with refractory bilateral granulomatous panuveitis. Although no joint involvement was evident, she exhibited skin lesions on her legs; a skin biopsy revealed granulomatous dermatitis, and *P. acnes* was detected within the sarcoid granulomas by immunohistochemistry with *P. acnes*-specific monoclonal (PAB) antibody. Genetic analyses revealed that the patient had a NOD2 heterozygous D512V mutation that was novel and not present in either of her parents. The mutant NOD2 showed a similar activation pattern to EOS/BS, thus confirming her diagnosis. After starting oral prednisolone treatment, she experienced an anterior vitreous opacity relapse despite gradual prednisolone tapering; oral methotrexate was subsequently administered, and the patient responded positively.

**Conclusions:** We presented a case of EOS/BS with a novel D512V mutation in the NOD2 gene. In refractory granulomatous panuveitis cases without any joint involvement, EOS/BS should be considered as a differential diagnosis; genetic analyses would lead to a definitive diagnosis. Moreover, this is the first report of *P. acnes* demonstrated in granulomas of EOS/BS. Since intracellular *P. acnes* activates nuclear factor-kappa B in a NOD2-dependent manner, we hypothesized that the mechanism of granuloma formation in EOS/BS may be the result of NOD2 activity in the presence of the ligand muramyl dipeptide, which is a component of *P. acnes*. These results indicate that recognition of *P. acnes* through mutant NOD2 is the etiology in this patient with EOS/BS.

**Keywords:** D512V mutation, Granulomatous disease, Methotrexate, NF-κB, NOD2, *Cutibacterium acnes*, PAB antibody
Background
Sarcoidosis is a multiorgan inflammatory disease with unknown etiology, characterized by the histological features of noncaseating epithelioid cell granulomas [1]. Two distinct types of sarcoidosis have been reported in children: classic sarcoidosis (CS) and early-onset sarcoidosis (EOS) [1, 2]. The former, clinically characterized by a triad of lung, lymph node, and eye involvement, similar to its manifestation in adults, presents in older children and is detectable via chest radiography. The latter is quite rare and found in younger children, presenting with a triad of skin, joint, and eye disorders with no apparent pulmonary involvement.

EOS and Blau syndrome (BS) are systemic inflammatory granulomatous diseases [1, 3]. The pathophysiology is the same for both diseases; however, differentiation between the sporadic and familial (autosomal dominant inheritance) forms is possible [3]. Clinically, in both diseases, the cutaneous and articular symptoms primarily appear in children aged < 4 years [4–6], while ocular manifestations typically appear between the ages of 7 and 12 years [7]. On the other hand, the most common morbidity associated with EOS/BS is ocular involvement that is usually refractory to conventional treatment, including continuous local and systemic glucocorticoids [8].

In 2001, NOD2 was identified on chromosome 16q12 as the gene responsible for EOS/BS [1, 3, 7, 9]. The NOD2 gene is intracellularly expressed in phagocytic cells and recognizes muramyl dipeptide (MDP), a component of the bacterial peptidoglycan, inducing an immune response through nuclear factor-kappa B (NF-κB) activation. NOD2 mutations in patients with EOS/BS enhance the self-oligomerization of NOD2, leading to augmented NOD2 activity even in the absence of the ligand MDP; further increases in activity by the addition of ligands represent gain-of-function mutations, consistent with the dominant mode of inheritance of the granulomatous disease [10, 11]. However, genetic screening of the NOD2 gene revealed no common mutations in Japanese and Caucasian CS patients [12, 13].

Despite a number of relevant studies, little is known about the relationship between the activation of NOD2 and the pathophysiology of EOS/BS [14]. The etiologic aspect of CS as an allergic endogenous infection has recently been elucidated; CS is most likely the result of a complex interaction between infection, immunity, and allergic reaction. Sarcoid granulomas form in patients with a hypersensitive immune response to Propionibacterium acnes (P. acnes). They are formed primarily as a host defense mechanism against intracellular P. acnes activated at the sites of latent infection to prevent the spread of the infectious agent [15].

Conversely, no reports have described the association between EOS/BS and P. acnes. Contrary to the asymptomatic and sometimes naturally resolving form of the disease found in CS, EOS/BS is progressive and often leads to poor prognoses, such as blindness or joint destruction [16]. Clarifying the pathogenesis of EOS/BS is essential for preventing a poor prognosis. Considering all these factors, we describe here a case of EOS/BS with a novel mutation in the NOD2 gene as well as the presence of P. acnes in the granulomatous inflammation of the biopsied skin tissue.

Case presentation
During early infancy, a Japanese girl developed papules on her legs and the dorsum of her hands. While the condition remained undiagnosed, the papules on her hand disappeared spontaneously at the age of 4 years. At age 5, she developed both conjunctival hyperemia and photophobia in her left eye; she was diagnosed with anterior uveitis, which was effectively treated using localized therapy. At age 7.5, she developed central scotoma and sudden visual loss (left > right) that was diagnosed as granulomatous panuveitis, which was effectively treated using local glucocorticoid therapy.

By age 8, the granulomatous panuveitis had flared up again; anterior chamber inflammation was seen in both eyes, and mydriasis had developed in the right eye due to posterior synechiae (Fig. 1a). The fundus was characterized by bilateral multifocal choroiditis presenting as creamy yellow lesions, and a scar was seen in the macular region of her left eye (Fig. 2). Systemic glucocorticoid therapy was therefore needed to preserve sight in the left eye. Laboratory tests showed hemoglobin level (11.9 g/dL), white blood cell count (6.22 × 10^9 /L), platelet count (292 × 10^9 /L), showed hemoglobin level (11.9 g/dL), white blood cell count (6.22 × 10^9 /L), platelet count (292 × 10^9 /L), erythrocyte sedimentation rate (5 mm/h; reference range [RR], 5–15 mm/h), C-reactive protein level (0.01 mg/dL; RR, < 0.27 mg/dL), and matrix metalloproteinase-3 (16.4 ng/mL; RR, < 20.0 ng/mL); the tests for antinuclear antibodies and rheumatoid factor were negative. Her immunological tests were normal, and there were no episodes of recurrent or severe bacterial or fungal infection. Therefore, no additional tests, such as a flow cytometric dihydroorhodamine neutrophil respiratory burst assay, were performed to rule out chronic granulomatous disease. Magnetic resonance imaging of the extremities was carried out to evaluate the presence of arthritis; no abnormalities were detected.

A skin biopsy from papules on her leg indicated granulomatous dermatitis (Figs. 1b and c and 3). The biopsy samples were examined by immunohistochemistry (IHC) with a P. acnes-specific monoclonal antibody (PAB antibody, D371-3, MEDICAL & BIOLOGICAL
LABORATORIES CO., LTD., Aichi, Japan) and a mycobacteria-specific monoclonal antibody (LAM antibody, D372-3, MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.), according to the methods described in the original study [17]. The PAB antibody detected several signals of round bodies within the sarcoid granulomas and in lesions infiltrated by inflammatory cells, while no positive signal was observed using the LAM antibody as control (Fig. 4). The sarcoid granulomas were comprised of CD4+ cells and CD68+ cells; CD8+ cells were rarely observed in the dermis and subcutaneous tissue (Fig. 5).

Genetic analyses were performed of both the patient’s and her parents’ NOD2 genes. Genomic DNA was extracted from the peripheral blood of the patient and her parents, and all 12 exons of the NOD2 gene, including exon-intron boundaries, were amplified by polymerase chain reaction and sequenced by Sanger method. Results revealed that the patient had a heterozygous c.1535A > T mutation on exon 4 in the nucleotide-binding domain of NOD2, while her parents did not. Analysis of the protein variant revealed that the mutation was D512V (p.Asp512Val) (Fig. 6). An NF-κB luciferase assay was performed. HEK293T cells (1 × 10⁵) were cotransfected with 30 ng of the expression construct of the NOD2 variant together with an NF-κB reporter plasmid. NF-κB activity was measured after 12 h of incubation either with or without 5 µg/mL MDP. A mock vector and the wild-type NOD2 were used as controls [1]; R334W and H496L were used as positive controls [1]. An in vitro assessment of the mutation indicated an increased basal NF-κB activity that increased further after MDP.

**Fig. 1** Clinical findings. a Anterior chamber inflammation in both eyes and mydriasis due to posterior synechiae in the right eye. b and c Asymptomatic diffuse papules on the extensor surfaces of the legs (arrows)

**Fig. 2** Fundus photograph. Right (a) and left (b) eyes showing bilateral multifocal choroiditis (arrowheads) presenting as creamy yellow lesions and a scar (arrow) in the macular region of the left eye
stimulation [18], demonstrating a strong association with EOS/BS. Based on her clinical, histological, and genetic features, the patient was diagnosed with EOS/BS despite the absence of arthritis during the course of the disease. She was treated with oral prednisolone (PSL) (1.5 mg/kg/day). Six months after initiating treatment, she experienced a relapse of anterior vitreous opacity while on a 0.3 mg/kg/day dose of oral PSL, which was then gradually tapered. Oral methotrexate (10 mg/m²/week) was prescribed as an additional treatment, to which there was a positive response. She has remained in clinical remission for over three years on a 0.1 mg/kg/day dose of oral PSL with methotrexate.

**Discussion**

This report describes a case of EOS/BS with a novel D512V mutation in the *NOD2* gene and a lack of...
Fig. 5 Immunohistochemical findings of CD4\(^+\), CD8\(^+\), and CD68\(^+\) cells. Large granulomas in the dermis and subcutaneous tissue were comprised of CD4\(^+\) cells (a and d), and CD68\(^+\) cells (b and e). CD8\(^+\) cells were rarely detected (c and f). Scale bar; 200 \(\mu\)m

Fig. 6 NOD2 heterozygous mutation. The electropherogram shows the sequence of heterozygous c.1535A \(\rightarrow\) T transition in exon 4 of the nucleotide-binding oligomerization domain in the patient (red arrow). No such mutation was found in her parents (black arrows). NOD2, nucleotide-binding oligomerization domain-containing protein 2.
arthritis. *P. acnes* was also detected in the granulomatous inflammation, which leads to the elucidation of the etiology of EOS/BS.

Our patient did not show any symptoms of arthritis. However, the most common manifestation of EOS/BS is symmetric and usually painless polyarthritis [19]. Only three mutations, E383K, R587C, and R334W, were identified previously in EOS/BS patients without arthritis [18, 20]. The R334W mutation in the *NOD2* gene is one of the most frequently occurring mutations in patients with EOS/BS [18, 20]. The patient with R587C mutation was a familial case with an age of onset of 216 months, and demonstrated skin rash without arthritis and uveitis [20]. Her daughter, who had the same mutation, was the proband of the disease and had rash, uveitis, and arthritis with an age of 21 months at onset [20]. It may be difficult to identify phenotypic variations, such as the timing and site of onset and the clinical severity of EOS/BS, according to the *NOD2* genotype. Nongenetic factors such as environmental conditions and/or infectious agents might be involved in phenotypic variation and clinical severity. Therefore, in individuals with *NOD2* mutations, *P. acnes* might be the trigger for onset of the disease and may determine the onset site by causing intracellular proliferation from a latently infected state. In our patient, translocation of *P. acnes* after local proliferation at the early onset site of the skin may have caused latent infection only in the eye (but not in the joint), where later reactivation caused uveitis (but not arthritis).

Our patient had a novel D512V mutation of the *NOD2* gene. Functional analysis showed elevated background activity and augmented activity after ligand stimulation, demonstrating a strong association with EOS/BS. A recent report elucidated the etiologial aspect of CS as an allergic endogenous infection caused by *P. acnes* [15]. Histological localization of *P. acnes* within sarcoid granulomas of the lymph nodes has been demonstrated by *in situ* hybridization [21] and IHC with PAB antibodies [17], suggesting that *P. acnes* is related to the cause of granuloma formation in CS. *P. acnes* has also been found in the cutaneous sarcoid granulomas of CS patients by IHC with PAB antibodies [22–26]. PAB antibody is a *P. acnes*-specific monoclonal antibody that reacts with lipoteichoic acids that are membrane-anchored molecules in the cell envelopes of gram-positive bacteria. In our case, using the same PAB antibody used in the previous studies, IHC detected several round bodies of *P. acnes* both within and around the sarcoid granulomas. The granulomas were comprised of CD4+ and CD68+ cells, indicating that they formed by the accumulation of CD4+ T-lymphocytes and macrophages. Therefore, the granulomas may have developed as a Th1 immune response to *P. acnes*.

*P. acnes* has also been demonstrated in ocular CS lesions. Nagata et al. [27] reported that *P. acnes* was present within granulomas in 10 (83 %) of 12 retinal biopsy samples from 9 (82 %) of 11 patients with ocular CS, whereas it was not detected in any (0 %) of the control group; the bacteria were identified as round bodies that reacted with PAB antibody. The retina is an aseptic environment and the presence of *P. acnes* within the retina is extremely unusual; therefore, detection of *P. acnes* within the retina was a critical observation, confirming the role of *P. acnes* as an etiological agent for CS. *P. acnes* is commensal on the skin, including sebaceous follicles, but usually absent in the dermis; therefore, we considered that detection of *P. acnes* within the sarcoid granulomas in the dermis strongly suggested *P. acnes* as an etiological agent for EOS/BS.

Tanabe et al. [28] found that both *NOD1* and *NOD2* proteins recognized intracellular *P. acnes*. Furthermore, systematic searches for *NOD1* gene polymorphisms in Japanese CS patients identified an increased frequency of G796A. Functional analysis revealed that *NOD1* G796A was associated with a lower expression at the protein level, leading to reduced NF-kB activation in response to intracellular *P. acnes*. These results indicated that impaired recognition of intracellular *P. acnes* through *NOD1* variants might cause susceptibility to CS within the Japanese population. We, therefore, hypothesized that the mechanism of granuloma formation in EOS/BS may be the result of *NOD2* hyperactivity in the presence of the ligand MDP, a component of *P. acnes*.

We found that EOS/BS and CS share a common feature of *P. acnes* in granulomatous pathology; however, the reason for the differing clinical features (especially the different triad of symptoms) between EOS/BS and CS remains unknown. It may be related to the presence or absence of *NOD2* mutations, or different sites of preceding latent infection of *P. acnes* in EOS/BS and CS. The lack of arthritis in our patient may indicate the lack of latent infection. Additionally, it remains unknown how the hyperactivity of NF-kB without MDP stimulation is involved in the pathophysiology of EOS/BS. The gain-of-function *NOD2* mutations found in EOS/BS patients may cause an excessive immune response to *P. acnes*, with increased *NOD2* activity in the presence of MDP; this excessive immune response to *P. acnes* would lead to poor prognosis.

Nagakura et al. [29] reported that tumor necrosis factor inhibitors provide long-term clinical benefits in EOS/BS. Thus, it would be one of the candidate treatments in the case of a later relapse. Furthermore, according to the identification of *P. acnes* in our patient, a combination of antibiotic and symptomatic therapy might be considered as a novel treatment for EOS patients. Antibiotics against *P. acnes* may be effective for patients with
progressive CS by preventing relapses of inflammation caused by repeated reactivation of the latent bacteria [15]. The result of a nationwide questionnaire survey, performed by a Japanese research group in 2005, indicated that antibiotic therapy was effective in 43% of patients with CS treated with several kinds of antibiotics, including minocycline, doxycycline, and clarithromycin [15]. This study therefore provides scope for future research.

Conclusions
In summary, we presented a case of EOS/BS with a novel D512V mutation in the NOD2 gene. In refractory granulomatous panuveitis cases without joint involvement, EOS/BS should be considered as a differential diagnosis; genetic analyses would lead to a definite diagnosis. Moreover, this is the first report of *P. acnes* demonstrated in granulomas of EOS/BS. Since intracellular *P. acnes* activates NF-κB in a NOD2-dependent manner, we hypothesized that the mechanism of granuloma formation in EOS/BS may be the result of NOD2 activity in the presence of the ligand MDP, which is a component of *P. acnes*. These results indicate that recognition of *P. acnes* through mutant NOD2 is the etiology in this patient with EOS/BS.

Additional information
This patient is the same as the D512V case reported in reference number 18. There was no polyarthritis or renal calcification in this patient. In fact, the statement that polyarthritis and renal calcification were present is an error made by the authors of reference number 18, and is currently being corrected by them for submission of an erratum.

Abbreviations
BS: Blau syndrome; CS: Classic sarcoidosis; EOS: Early-onset sarcoidosis; IHC: Immunohistochemistry; LAM: Mycobacteria-specific monoclonal; MDP: Muramyl dipeptide; NF-κB: Nuclear factor-kappa B; NOD2: Nucleotide-binding oligomerization domain-containing protein 2; PAB: Propionibacterium acnes-specific monoclonal; P. acnes: Propionibacterium acnes; PSL: Prednisolone; RR: Reference range

Acknowledgements
We thank the patient, her family, and their friends for their cooperation. We would like to thank Editage (www.editage.com) for English language editing.

Authors’ contributions
OF, WH, TT, EY, and HS wrote the paper; OF, WH, KY, NT, YH, US, and YR treated the patient; AN, HY, UK, and EY performed the pathological studies; TT, IK, HY, and NR performed the genetic study; WH, OS, and HS conducted and designed the research; all authors read and approved the final manuscript.

Funding
This work was supported in part by JSPS KAKENHI Grant Number JP19K17908.

Availability of data and material
Not applicable.

Ethics approval and consent to participate
The need for formal approval was waived.

Consent for publication
Informed consent was obtained from the patient’s guardian for publication of this case report.

Conflict of Interest
The authors declare that they have no competing interests.

Author details
1Department of Pediatrics, Yamaguchi University Graduate School of Medicine, 1-1-1 Minamikogushi, 755-8505 Ube, Yamaguchi, Japan.
2Department of Ophthalmology, Yamaguchi University Graduate School of Medicine, Ube, Japan.
3Department of Dermatology, Yamaguchi University Graduate School of Medicine, Ube, Japan.
4Department of Diagnostic Pathology, Yamaguchi University Graduate School of Medicine, Ube, Japan.
5Department of Pediatric and Child Health, Kurume University School of Medicine, Kurume, Japan.
6Department of Public Health and Preventive Medicine, Yamaguchi University Graduate School of Medicine, Ube, Japan.
7Department of Pediatrics, Kyoto University Graduate School of Medicine, Kyoto, Japan.
8Department of Human Pathology, Tokyo Medical and Dental University Graduate School, Tokyo, Japan.
9Department of Pediatrics, Graduate School of Medical Science, Kyushu University, Fukuoka, Japan.
10Department of Pediatrics, Kurume University School of Medicine, Kurume, Japan.

Received: 21 July 2020 Accepted: 8 February 2021
Published online: 18 February 2021

References
1. Kanazawa N, Okafuji I, Kambe N, Nishikomori R, Nakata-Hizume M, Nagai S, et al. Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor-kappaB activation: common genetic etiology with Blau syndrome. Blood. 2005;105:1195–7.
2. Shetty AK, Gedalia A. Sarcoidosis: a pediatric perspective. Clin Pediatr (Phila). 1998;37:707–17.
3. Miceli-Richard C, Lesage S, Rybojad M, Prieur AM, Manouvrier-Hanu S, Häfner R, et al. CARD15 mutations in Blau syndrome. Nat Genet. 2001;29:19–20.
4. Becker ML, Rose CD. Blau syndrome and related genetic disorders causing childhood arthritis. Curr Rheumatol Rep. 2005;7:427–33.
5. Rose CD, Wouters CH, Meicotin S, Doyle TM, Davey MP, Rosenbaum JT, et al. Pediatric granulomatous arthritis: an international registry. Arthritis Rheum. 2006;54:3337–44.
6. Arostegui JI, Arnal C, Merino R, Modesto C, Carballo MA, Moreno P, et al. NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort. Arthritis Rheum. 2007;56:3805–13.
7. Srifo P, Caso F, Tognon S, Galozzi P, Gava A, Punzi L. Blau syndrome, clinical and genetic aspects. Autoimmun Rev. 2012;12:444–51.
8. Sairens IL, Casteels I, Anton J, Bader-Meurier B, Bissauud P, Chedeville G, et al. Blau syndrome-associated uveitis: preliminary results from an international prospective interventional case series. Am J Ophthalmol. 2018;187:158–66.
9. Achille M, Ilaria P, Teresa G, Roberto C, Ilir A, Piergiorgio N, et al. Successful treatment with adalimumab for severe multifocal choroiditis and panuveitis in presumed (early-onset) ocular sarcoidosis. Int Ophthalmol. 2016;36:129–35.
10. Tanabe T, Chamallard M, Ogura Y, Zhu L, Qiu S, Masumoto J, et al. Regulatory regions and critical residues of NOD2 involved in muramyl dipeptide recognition. EMBO J. 2004;23:1587–97.
11. Yamaguchi N, Suzuki Y, Mahbub MH, Takahashi H, Hase R, Ishimaru Y, et al. The different roles of innate immune receptors in inflammation and carcinogenesis between races. Environ Health Prev Med. 2017;22:70.
12. Akahoshi M, Ishihara M, Namba K, Kitaichi N, Ando Y, Takenaka S, et al. Mutation screening of the CARD15 gene in sarcoidosis. Tissue Antigens. 2008;71:564–7.
13. Schurmann M, Valentynre RT, Hampe J, Muller-Quernheim J, Schwingen E, Schreiber S. CARD15 gene mutations in sarcoidosis. Eur Respir J. 2003;22:748–54.
14. Girardin SE, Boneca IG, Viala J, Chamaillard M, Labigne A, Thomas G, et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem. 2003;278:8869–72.

15. Eishi Y. Etiologic aspect of sarcoidosis as an allergic endogenous infection caused by Propionibacterium acnes. Biomed Res Int. 2013;2013:935289.

16. Fink CW, Cimaz R. Early onset sarcoidosis not a benign disease. J Rheumatol. 1997;24:174–7.

17. Negi M, Takemura T, Guzman J, Uchida K, Furukawa A, Suzuki Y, et al. Localization of Propionibacterium acnes in granulomas supports a possible etiologic link between sarcoidosis and the bacterium. Mod Pathol. 2012;25:1284–97.

18. Matsuda T, Kambe N, Ueki Y, Kanazawa N, Izawa K, Honda Y, et al. Clinical characteristics and treatment of 50 cases of Blau syndrome in Japan confirmed by genetic analysis of the NOD2 mutation. Ann Rheum Dis. 2020. doi:https://doi.org/10.1136/annrheumdis-2020-217320.

19. Milman N, Ursin K, Rødevand E, Nielsen FC, Hansen TVO. A novel mutation in the NOD2 gene associated with Blau syndrome: a Norwegian family with four affected members. Scand J Rheumatol. 2009;38:190–7.

20. Rosé CD, Aróstegui JJ, Martin TM, Espada G, Scalzi L, Yagüe J, Rosenbaum JT, et al. NOD2-associated pediatric granulomatous arthritis, an expanding phenotype: Study of an International Registry and a National Cohort in Spain. Arthritis Rheum. 2009;60:1797–803.

21. Yamada T, Eishi Y, Ikeda S, Ishige I, Suzuki T, Takemura T, et al. In situ localization of Propionibacterium acnes DNA in lymph nodes from sarcoidosis patients by signal amplification with catalysed reporter deposition. J Pathol. 2002;191:541–7.

22. Akahina A, Miura K, Saito I, Oshikata C, Ishii N, Eishi Y. Cutaneous sarcoidosis with livedoid lesions: evidence of the involvement of Propionibacterium acnes. J Dermatol. 2013;40:501–2.

23. Takama H, Yanagishita T, Muto J, Ohshima Y, Takahashi E, Tsuzuki T, et al. Granulomatous pigmented purpuric dermatosis containing Propionibacterium acnes. Eur J Dermatol. 2018;28:540–2.

24. Sasaki S, Kato M, Nakamura K, Namba Y, Nagashima O, Takahashi K. Management of skin sarcoidosis with minocycline monotherapy. Respirol Case Rep. 2019;7:e00413.

25. Noda S, Maeda A, Komya Y, Soejima M. A Patient with necrotizing vasculitis related to sarcoidosis, which was diagnosed via immunohistochemical methods using P. acnes-specific monoclonal antibodies. Intern Med. 2020;10:943–20.

26. Inoue Y, Teraki Y. Association of Propionibacterium acnes with the efficacy of minocycline therapy for cutaneous sarcoidosis. Int J Dermatol. 2020;59:704–8.

27. Nagata K, Eishi Y, Uchida K, Yonedo K, Hatanaka H, Yasuhara T, et al. Immunohistochemical detection of Propionibacterium acnes in the retinal granulomas in patients with ocular sarcoidosis. Sci Rep. 2017;7:15526.

28. Tanebe T, Ishige I, Suzuki Y, Aita Y, Furukawa A, Ishige Y, et al. Sarcoidosis and NOD1 variation with impaired recognition of intracellular Propionibacterium Acnes. Biochim Biophys Acta. 2006;1762:794–801.

29. Nagakura T, Wakiyama S, Kubota T, Yamaout T, Yamazaki Y, Nonaka Y, et al. Tumor necrosis factor inhibitors provide longterm clinical benefits in pediatric and young adult patients with Blau syndrome. J Rheumatol. 2017;44:536–8.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.